Sudeep Pharma makes a strong market entry; lists at 23% premium on NSE, investors earn notable listing gains
The stock opened at ₹730 on NSE against the issue price of ₹593, translating into a gain of ₹18,250 for the retail investors on every allotted lot
Sudeep Pharma IPO listing sees impressive returns for subscribers
Sudeep Pharma started on a high note as its shares made their debut on the stock exchanges on Friday, November 28, 2025. The stock started off trading on the NSE at ₹730, which is a gain of 23.10% over the IPO price of ₹593 per share. On the BSE, it listed marginally higher at ₹733.95, up 23.77% over the issue price. Such a strong beginning underlined the positive market sentiment for the company.
The IPO comprised a fresh share issue of ₹95 crore along with an OFS totaling ₹800 crore, which took the total issue size to ₹895 crore. The minimum application size was 25 shares, which means retail investors who got one lot earned a listing-day profit of ₹18,250. The strong premium on listing brought substantial early gains to those who got allotment.
The demand for the public issue was exceptionally high, with overall subscription reaching 93.72 times. Against 10.56 crore shares available, investors applied for more than 99 crore shares. The QIB segment subscribed 213.08 times, NIIs subscribed 116.72 times, and the retail category received bids 15.65 times its share, indicating widespread interest across investor classes.
According to the company’s red herring prospectus, the proceeds from the fresh issue would be used for buying new machinery for its Nandesari production unit and meeting general corporate purposes. The strong listing is likely to aid the company’s future expansion plans.
